| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/25/2002 | WO2002057261A2 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 07/25/2002 | WO2002057260A1 Compounds for use in the treatment of skin conditions |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057258A1 Cyclo`d!azepane derivatives which are used as farnesyltransferase inhibitors and method for the preparation thereof |
| 07/25/2002 | WO2002057257A1 Cyclo`c!azepane derivatives which are used as farnesyltransferase inhibitors and method for the preparation therefor |
| 07/25/2002 | WO2002057244A1 Phenothiazine kinesin inhibitors |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057236A1 Phenyl derivatives |
| 07/25/2002 | WO2002057226A2 68730 and 69112 protein kinase molecules and uses therefor |
| 07/25/2002 | WO2002057223A2 Compounds azepane, preparation method therefor and pharmaceutical compositions containing said compounds |
| 07/25/2002 | WO2002057222A2 Thiol-based naaladase inhibitors |
| 07/25/2002 | WO2002056917A1 A recombination virus able to specifically kill tumor associated with eb virus and the constructing method thereof |
| 07/25/2002 | WO2002056916A2 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 07/25/2002 | WO2002056912A2 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| 07/25/2002 | WO2002056910A1 Binding domain-immunoglobulin fusion proteins |
| 07/25/2002 | WO2002056907A2 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | WO2002056905A2 Molecular antigen array |
| 07/25/2002 | WO2002056903A2 Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| 07/25/2002 | WO2002056894A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent |
| 07/25/2002 | WO2002056893A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | WO2002056886A1 Angiogenesis inhibitors contaiing urea derivative as the active ingredient |
| 07/25/2002 | WO2002056885A1 Camptothecin derivatives |
| 07/25/2002 | WO2002056880A1 Triphenylmethane kinesin inhibitors |
| 07/25/2002 | WO2002056874A2 Lipid-based nitric oxide donors |
| 07/25/2002 | WO2002056872A2 Antiproliferative colchicine compositions and uses thereof |
| 07/25/2002 | WO2002056835A2 Anticancer treatment using triptolide prodrugs |
| 07/25/2002 | WO2002056823A2 Redox therapy for tumors |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002056755A2 Method for treating cancer |
| 07/25/2002 | WO2002056753A2 P27 prevents cellular migration |
| 07/25/2002 | WO2002056708A2 Preparation for improved dietary utilisation |
| 07/25/2002 | WO2002056692A1 Methods for modulating tumor growth and metastasis |
| 07/25/2002 | WO2002044161A3 A process for the preparation of taxan derivatives |
| 07/25/2002 | WO2002043663A3 Tetrapartate prodrugs |
| 07/25/2002 | WO2002043652A3 Anti-proliferative drugs |
| 07/25/2002 | WO2002040041A3 Orally ingestible preparation of mistletoe lectins and method |
| 07/25/2002 | WO2002039988A3 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032874A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002020039A3 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
| 07/25/2002 | WO2002018379A3 7-oxo pyridopyrimidines |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002014489A3 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2002008177A3 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 07/25/2002 | WO2002002147A3 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 07/25/2002 | WO2002000894A3 Gene silencing vector |
| 07/25/2002 | WO2002000653A3 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 07/25/2002 | WO2001094413A3 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 07/25/2002 | WO2001093877A3 Epithelial cell cancer drug |
| 07/25/2002 | WO2001088126A3 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 07/25/2002 | WO2001087307A3 Compositions and methods for the treatment of cancer |
| 07/25/2002 | WO2001085940A3 USE OF hTAFII80 AND ISOFORMS THEREOF FOR INDUCING APOPTOSIS |
| 07/25/2002 | WO2001078701A3 Method and compositions for preventing hormone induced adverse effects |
| 07/25/2002 | WO2001074346A3 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 07/25/2002 | WO2001070798A3 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 07/25/2002 | WO2001064904A3 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor |
| 07/25/2002 | WO2001064193A3 Exemestane for first-line treatment of breast cancer |
| 07/25/2002 | WO2001062289B1 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 07/25/2002 | WO2001060992A3 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 07/25/2002 | WO2001045690A3 Use of bvdu for inhibiting the growth of hyperproliferative cells |
| 07/25/2002 | WO2001040188A9 Curcumin analogues for treating cancer |
| 07/25/2002 | WO2001036048A9 Phorboxazole derivatives for treating cancer |
| 07/25/2002 | WO2001034201A9 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 07/25/2002 | WO2001032204A3 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 07/25/2002 | WO2001025275A9 Regulatory/unfolding peptides of ezrin |
| 07/25/2002 | WO2001009187A9 Human monoclonal antibodies to her2/neu |
| 07/25/2002 | WO2001004157A9 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 07/25/2002 | WO2001003716A9 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 07/25/2002 | WO2001002567A9 16405 receptor, a g-protein coupled receptor |
| 07/25/2002 | WO2001000829A9 Human endogenous retrovirus in breast cancer |
| 07/25/2002 | WO2001000812A9 22012, a novel human carboxypeptidase |
| 07/25/2002 | WO2001000811A9 17867, a novel human aminopeptidase |
| 07/25/2002 | US20020099222 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 07/25/2002 | US20020099215 For therapy and prophylaxis of P-glycoprotein-mediated multidrug resistance |
| 07/25/2002 | US20020099211 9-alkylamino-1-nitroacridine derivatives |
| 07/25/2002 | US20020099209 Dihydrostilbene alkanoic acid derivatives |
| 07/25/2002 | US20020099207 Has activity as an antagonist to neurokinin 1 receptors; for therapy of benign prostatic hyperplasia (BPH) |
| 07/25/2002 | US20020099191 EDG8 receptor, its preparation and use |
| 07/25/2002 | US20020099190 Nuclelotide sequences coding protein for use in the treatment and prevention of atherosclerosis, osteoporosis and nervous system disorders |
| 07/25/2002 | US20020099181 Anti-fibroblast growth factor-8 monoclonal antibody |
| 07/25/2002 | US20020099178 Growth-associated protease inhibitor heavy chain precursor |
| 07/25/2002 | US20020099096 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer |
| 07/25/2002 | US20020099089 Administering compounds such as trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide or like for therapy of conditions associated with increased telomerase activity, e.g. tumour diseases |
| 07/25/2002 | US20020099087 Vanadium (iv) metallocene complexes having spermicidal activity |
| 07/25/2002 | US20020099071 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia |
| 07/25/2002 | US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis |
| 07/25/2002 | US20020099066 Antitumour 1,5-diazaanthraquinones |
| 07/25/2002 | US20020099065 Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents |
| 07/25/2002 | US20020099057 Treatment of accidental extravasation of anthracyclines |
| 07/25/2002 | US20020099051 Anticancer treatment using triptolide prodrugs |
| 07/25/2002 | US20020099028 Genes and genetic elements associated with control of neoplastic transformation in mammalian cells |
| 07/25/2002 | US20020099020 Oil blend of omega-3- and omega-6- fatty acids; branched amino acid; antioxidant comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof; in a liquid nutritional matrix. |
| 07/25/2002 | US20020099012 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020099007 And the prenylation of the oncogene protein Ras; peptidomimetic macrocyclic compounds |
| 07/25/2002 | US20020098998 P27 prevents cellular migration |
| 07/25/2002 | US20020098980 Sodium metasilicate, borax, sodium thiosulfate, potassium carbonate, refined sugar, water; improvement in disease resistance, weight gain rate, crop yield, crop quality, harvest time; antibody production and immune enhancement |